SMARCB1-deficient malignancies

Clinical trials for SMARCB1-deficient malignancies explained in plain language.

Never miss a new study

Get alerted when new SMARCB1-deficient malignancies trials appear

Sign up with your email to follow new studies for SMARCB1-deficient malignancies, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Promising new therapy targets rare, aggressive cancers

Disease control Ongoing

This study tests whether the drug ubamatamab, alone or with cemiplimab, can help control rare cancers like renal medullary carcinoma and epithelioid sarcoma. About 40 adults with advanced or metastatic disease will receive the treatment to check safety and effectiveness. The goal…

Matched conditions: SMARCB1-DEFICIENT MALIGNANCIES

Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Aug 08, 2026 00:03 UTC

SMARCB1-deficient malignancies

Get alerted when new SMARCB1-deficient malignancies trials appear

Promising new therapy targets rare, aggressive cancers